CAR-T Cells Targeting Membrane-Inserted Ligands
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapies face challenges in effectively targeting and treating solid tumors due to heterogeneous tumor antigen expression and off-target activities in healthy tissues.
Innovation Solution
Introducing a membrane-inserting amphiphilic ligand, such as fluorescein isothiocyanate lipid amphiphile, into tumors, followed by administering engineered immune cells expressing CARs that specifically bind to these ligands, allowing for targeted recognition and destruction of tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CAR-T cell therapy is used to target tumor cells, then immune cells can recognize and attack tumor antigens, but heterogeneous tumor antigen expression and off-target activities in healthy tissues reduce treatment specificity and efficacy
Solution Approach 1:
The amphiphilic ligand is introduced into the tumor before administering the CAR-T cells. This preliminary tagging of tumor cells with the ligand creates a specific target that the CAR-T cells can recognize, ensuring that the immune cells are directed to the tumor site before treatment begins, thereby improving specificity and reducing off-target effects
Solution Approach 2:
The membrane-inserting amphiphilic ligand serves as an intermediary between the CAR-T cells and the tumor cells. The ligand is inserted into the tumor cell membrane and acts as a bridge that the CAR-T cell receptor can specifically bind to, enabling precise targeting without requiring the CAR-T cells to directly recognize heterogeneous tumor antigens
2Adaptability or versatility
If CAR-T cells are administered to target heterogeneous tumor antigens, then broad coverage of tumor cells is achieved, but off-target activities in healthy tissues increase
Solution Approach 1:
The invention extracts the targeting function from the heterogeneous tumor antigens and concentrates it into a single, uniform amphiphilic ligand that is introduced into the tumor. This ligand is then recognized by the CAR-T cells, allowing broad tumor coverage while eliminating off-target activities because the ligand is only present in the tumor and not in healthy tissues
Solution Approach 2:
The amphiphilic ligand is locally introduced into the tumor tissue, creating a localized target that is specific to the tumor site. This local concentration of the ligand ensures that CAR-T cells are activated and directed only at the tumor location, providing broad coverage of tumor cells while preventing off-target effects in healthy tissues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the specificity and efficacy of immune cell targeting, reducing off-target effects and improving treatment outcomes for solid tumors by ensuring precise binding and activation of CAR-T cells to tumor cells.
Implementation Method 1
membrane-inserting amphiphilic ligand
Data Source
AI summary
The present disclosure relates generally to technologies comprising engineered immune cells that express chimeric antigen receptors (CARs) that specifically bind to a membrane-inserting amphiphilic ligand. Also disclosed herein are methods and compositions for treating a tumor.